302 East Pettigrew St.
About Precision BioSciences
Precision BioSciences is dedicated to improving life through its proprietary genome editing platform, “ARCUS.” Precision BioSciences leverages ARCUS in the development of its product candidates which are designed to treat human diseases and create healthy and sustainable food and agriculture solutions. Precision BioSciences is actively developing product candidates in three innovative areas: allogeneic CAR T immunotherapy, in vivo gene correction, and food.
Precision BioSciences: Culture
129 articles with Precision BioSciences
ACEA Biosciences, a biotechnology company that develops high performance cell analysis instruments, hosted their 6th annual Cancer Immunotherapy Symposium focused on CAR-T cell and TCR therapy on April 14, 2018 at the W Hotel in Chicago, prior to the 2018 AACR Annual Meeting.
Precision BioSciences Announces Appointment Of Gene Liau, Ph.D. And Bruce Mccreedy, Ph.D. To Management Team
Danziger Innovations And Precision BioSciences Announce Successful Genome Modification Collaboration In Ornamental Plants
Precision BioSciences And Agrivida, Inc. Announce Collaborative Trait Development Agreement And Successful Genetic Modification
Precision BioSciences Announces First Publication of Targeted Knockout Rats Using Engineered Meganuclease Technology
Precision BioSciences Announces Publication of Cotton Trait Stacking Success in Collaboration With Bayer CropScience AG
Precision BioSciences Announces Allowance of Eleventh U.S. Patent Application Related to Genome Editing Nucleases
Precision BioSciences Files Tenth Patent Infringement Lawsuit Against CELLECTIS SA Related to Meganuclease Technology and Requests Permanent Injunction
Precision BioSciences Files Ninth Patent Infringement Lawsuit Against CELLECTIS SA Related to Engineered Meganucleases
Precision BioSciences Files Seventh and Eighth Patent Infringement Lawsuits Against CELLECTIS SA, Seeks Permanent Injunction and Monetary Damages
Precision BioSciences Announces Sixth Patent Infringement Lawsuit Against CELLECTIS SA, Seeks Permanent Injunction Against Importation Into U.S.
Precision BioSciences Files Fifth Patent Infringement Lawsuit Against CELLECTIS SA Related to Engineered Meganucleases
Precision BioSciences Announces Allowance of Five Additional U.S. Patent Applications Related to Engineered Meganucleases